HER2 Support Group Forums - View Single Post

Rich66 · 10-08-2010, 11:14 AM

1. Roche CEO touts 'stunning' breast, lung cancer data

By Maureen Martino

Comment |

Forward |

Twitter |

Facebook |

LinkedIn Hours ahead of the 2010 European Society for Medical Oncology meeting in Milan, Roche CEO Severin Schwan (photo) is talking up data from two of his company's cancer drugs: T-DM1, a breast cancer treatment, and MetMab, a drug for lung cancer. "I think a lot of people will be very excited about what we have to present," said Schwan, as quoted by Reuters. "I think the T-DM1 results are stunning; MetMab results are stunning." The remarks were made at a press and analyst event in Tokyo.
In a head-to-head Phase II study, T-DM1 demonstrated a higher response rate and lower toxicity than Roche's blockbuster Herceptin. TheStreet notes that the results are significant since T-DM1 could eventually replace Herceptin. Immunogen is also partnered on the drug. More data on T-DM1 and MetMab will be presented at the meeting.

10-08-2010, 11:14 AM	#1
Rich66 Senior Member Join Date: Feb 2008 Location: South East Wisconsin Posts: 3,431	Roche to brag on TDM1 results 1. Roche CEO touts 'stunning' breast, lung cancer data By Maureen Martino Comment \| Forward \| Twitter \| Facebook \| LinkedIn Hours ahead of the 2010 European Society for Medical Oncology meeting in Milan, Roche CEO Severin Schwan (photo) is talking up data from two of his company's cancer drugs: T-DM1, a breast cancer treatment, and MetMab, a drug for lung cancer. "I think a lot of people will be very excited about what we have to present," said Schwan, as quoted by Reuters. "I think the T-DM1 results are stunning; MetMab results are stunning." The remarks were made at a press and analyst event in Tokyo. In a head-to-head Phase II study, T-DM1 demonstrated a higher response rate and lower toxicity than Roche's blockbuster Herceptin. TheStreet notes that the results are significant since T-DM1 could eventually replace Herceptin. Immunogen is also partnered on the drug. More data on T-DM1 and MetMab will be presented at the meeting. __________________ Mom's treatment history (link)